Listen to The Lancet Infectious Diseases

Dr Jenny Clarke and Herve Semukunzi discuss a study they and colleagues recently published with us titled ‘Infection- and vaccine-induced mpox antibodies: validation of a combined mpox IgG ELISA during the clade 1b outbreak in Rwanda’.

Dr Julia Moore Vogel and Dr Danilo Buonsenso discuss various aspects of long COVID including epidemiology, pathophysiology, underlying mechanisms, management, latest research developments, difficulties in conducting clinical trials, and future research priorities.

Professors Steven Tong and Joshua Davis discuss all aspects of adaptive platform trials including advantages, disadvantages, differences from conventional trials, and tips for setting up and assessing them.

Series authors discuss their papers on artificial intelligence and infectious diseases intended to support the infectious diseases community in understanding this evolving landscape.

Drs Catherine Liu and Joshua Hill of the Fred Hutchinson Cancer Center discuss their new Series of papers on the prevention and management of infections in people who are immunocompromised, with a focus on prevention of infections and diagnostic and antimicrobial stewardship.

Lilian Tina Minja and Norbert Heinrich discuss the SUDUCO and DECODE trials in The Lancet Infectious Diseases on two new promising TB drugs, sutezolid and delpazolid, respectively. They also discuss the wider implications of the findings of these trials for TB drug development and treatment.

Leonardo Basso and Juan Pablo Torres discuss their study in The Lancet Infectious Diseases on the effectiveness and impact of the first season of Chile's national immunisation programme with nirsevimab. They discuss the evidence that led to the design and implementation of the programme, its impact on RSV burden and the Chilean health system, and lessons for other countries in the region...

Jan Felix Drexler and Fernando Bozza discuss their recent study published in the journal— “The spatio-temporal ecology of Oropouche virus: a laboratory-based modelling study across Latin America” and its wider implications for Oropouche virus and other arboviruses transmission, expansion, surveillance, and control.

Prasad Kulkarni discusses a new Phase I trial in The Lancet Infectious Diseases on a dengue monoclonal antibody also known as VIS513 in healthy adults. In addition, he highlights the wider implications of this for dengue control and drug development.

Oriol Mitjà discusses a new trial in The Lancet Infectious Diseases on the use of oral linezolid compared with benzathine penicillin G for the treatment of early syphilis in adults. He also highlights what the trial means for treatment of syphilis.

Luciano Moreira and Henrik Salje discuss a new article in The Lancet Infectious Diseases describing the use of the Wolbachia bacteria to control the spread of mosquito-borne dengue and chikungunya in Rio de Janeiro, Brazil.

Richard Maude discusses a new article in The Lancet Infectious Diseases that assesses the efficacy of malaria chemoprophylaxis among forest goers in Cambodia.

Ben Cowling discusses a new article in The Lancet Infectious Diseases describing the protection that vaccines are providing against COVID-19 in Hong Kong.

Hugh Adler discusses a new article in The Lancet Infectious Diseases describing the management and the clinical features for seven patients with monkeypox hospitalised in the UK between 2018 and 2021.

Prof Beate Kampmann, Dr Karen Keddy, and Prof Peter Ghazal discuss a new cross-journal Series in The Lancet Infectious Diseases and EBioMedicine addressing the potential for and challenge of applying big data to childhood infectious diseases in LMICs

A new Article in  The Lancet Infectious Diseases highlights how changing immunity profiles motivate the need for better responses to outbreaks of polio in Africa.

Paul Chapman and colleagues presents the results of an innovative trial assessing the safety of vaccinating healthy volunteers with attenuated Necator americanus hookworm larvae.

Josep Llibre discusses a trial on the impact of same-day testing for SARS-CoV-2 infection before a concert on new COVID-19 cases in Ba rcelona, Spain.

Yap Boum (MSF) discusses his study done in Cameroon, which developed a promising testing strategy for COVID-19 to optimise the available resource.

Two studies in The Lancet Infectious Diseases describe how the spread of resistance to both dihydroartemisinin and piperaquine is compromising malaria therapy in South-East Asia

A trial investigates the use of a cocktail of phages for the therapy of infections in patients with burns.

Editor of The Lancet Infectious Diseases , John McConnell, discusses the 1918 influenza pandemic and the lessons that can be learnt from it with John Oxford and Jeffery Taubenberger.

Amir Shroufi discusses the early results assessing the safety and efficacy of the combination of bedaquiline and delamanid against drug-resistant tuberculosis.

John Beigel, an author, and Eddie Sullivan discuss a phase 1 study assessing the safety and tolerability of human antibodies manufactured in transchromosomic cows for treatment of MERS.

Valentina Cambiano discusses the cost-effectiveness of pre-exposure prophylaxis medication in the UK.